Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, PMID: 32402160
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC, PMID: 32997907
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer, PMID: 30345906
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial, PMID: 31122901
Pembrolizumab and atezolizumab in triple-negative breast cancer, PMID: 33015734
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial, PMID: 32966830
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial, PMID: 32416780
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial, PMID: 31786121
Atezolizumab for the treatment of breast cancer, PMID: 32067545
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, PMID: 27979383
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial, PMID: 32534646
Atezolizumab for the treatment of triple-negative breast cancer, PMID: 30474425
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer, PMID: 27903674
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study, PMID: 32502443
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, PMID: 27939400
Atezolizumab in the treatment of metastatic triple-negative breast cancer, PMID: 32450725
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial, PMID: 33333328
The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer, PMID: 30586539
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial, PMID: 32302702
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer, PMID: 32248356
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations, PMID: 31829747
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial, PMID: 31079938
Atezolizumab: A Review in Extensive-Stage SCLC, PMID: 32990939
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, PMID: 26952546
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial, PMID: 29268948
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation, PMID: 32352320
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial, PMID: 31959349
The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer, PMID: 32400223
Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma, PMID: 32888462
Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer, PMID: 32402168
Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC, PMID: 31728860
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial, PMID: 30347025
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials, PMID: 33166718
Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer, PMID: 31829043
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial, PMID: 33002436
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study, PMID: 30217492
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial, PMID: 31003911
A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis, PMID: 32858235
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, PMID: 30082870
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study, PMID: 28950298
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients, PMID: 31171876
Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma, PMID: 27981577
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab, PMID: 29080213
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer, PMID: 29777823
Atezolizumab for the treatment of breast cancer, PMID: 29690797
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors, PMID: 30918950
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer, PMID: 30977385
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials, PMID: 32115349
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma, PMID: 27571927
Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer, PMID: 29785577
For research use only. Not for human or drug use.
